問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1449Cases

2025-06-09 - 2029-11-26

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

  • Condition/Disease

    COPD with Type 2 inflammation

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2015-11-30 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-11-01 - 2030-12-01

Phase III

Active
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    膠囊劑 皮下注射劑 錠劑 凍晶注射劑及懸浮注射液

Participate Sites
7Sites

Recruiting7Sites

2025-06-30 - 2028-08-31

Others

Not yet recruiting
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub-study

  • Condition/Disease

    asthma

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2024-02-12 - 2026-06-01

Phase III

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjogren's Syndrome With Moderate-to-Severe Symptom State

  • Condition/Disease

    Sjogren's Syndrome

  • Test Drug

    Dazodalibep

Participate Sites
5Sites

Recruiting5Sites

2018-09-01 - 2026-10-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-12-01 - 2027-05-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2025-11-01 - 2030-09-30

Phase I

Not yet recruiting
A Phase 1b/2 Open-Label, Multicenter Study of RMC-9805 with or without RMC-6236, in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C

  • Condition/Disease

    RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Test Drug

    tablets

Participate Sites
5Sites

Not yet recruiting5Sites

2025-10-01 - 2027-08-31

Phase II

Active
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Condition/Disease

    RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D

  • Test Drug

    tablets

Participate Sites
5Sites

Not yet recruiting5Sites

2025-06-13 - 2030-06-30

Phase III

Active
An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (PMN) [PROMINENT]

  • Condition/Disease

    Primary Membranous Nephropathy (PMN)

  • Test Drug

    powder

Participate Sites
10Sites

Recruiting10Sites

1 33 34 35 36 37 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB